There is an enormous rise in liver diseases among people in the UK and as a result, it is considered to be the fifth most serious health issue. At the same time, mortality rates also increase due to long-term waiting for liver transplantation.
Probiotics are defined as beneficial bacteria that are consumed to boost the populations of more beneficial microbes. The importance of probiotics in health improvement seems to be growing worldwide with more awareness of the benefits. For this reason, numerous research works are currently being conducted in the field of probiotics.
Dicerna Pharmaceuticals and Boehringer Ingelheim today announced a research collaboration and license agreement to discover and develop novel RNAi therapeutics for the treatment of chronic liver diseases. Dicerna can get up to $201 million in upfront and success-based development and commercialization milestones for an undisclosed target.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.